Can I read Crizotinib Protocol for ROS1-Positive NSCLC on EtoBox?

Crizotinib Protocol for ROS1-Positive NSCLC by ELFinch is a document available to read on EtoBox.

What is Crizotinib Protocol for ROS1-Positive NSCLC about?

The BC Cancer Protocol LUAVCRIZR outlines the first-line treatment of ROS1-positive advanced non-small cell lung cancer (NSCLC) using crizotinib, requiring patients to have confirmed ROS1-positive tumors and no prior systemic therapy. Treatment involves administering crizotinib at 250 mg twice daily, with specific dose modifications for hematological, hepatic, and other adverse effects. Regular monitoring and precautions are necessary due to potential cardiotoxicity, respiratory issues, and drug interaction

Author

ELFinch

Language

EN